Login Register Cart 0
Generic placeholder image

Infectious Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5265
ISSN (Online): 2212-3989

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Mini-Review Article

In silico ADME/Pharmacokinetic and Target Prediction Studies of Ethambutol as Drug Molecule

Author(s): Arnav Ajinkya Joshi, Sakshi V. Khairnar and Hemchandra K. Chaudhari*

Volume 22, Issue 4, 2022

Published on: 25 February, 2022

Article ID: e050122199979 Pages: 7

DOI: 10.2174/1871526522666220105113357

Price: $65

Abstract

Background: The conventional approach for the development of any pharmaceutically active molecule is a time-consuming and costly process because the synthesis is followed by laboratory tests which are then followed by long clinical trials. Hence, a faster approach is desired. This article discusses Ethambutol, a frontline anti-tubercular drug that has its properties predicted by the SwissADME tool and the results would be compared with the findings published in the literature.

Objective: The main objective is to study the predicted and experimental ADME properties, compare them and study the predicted targets and understand the use of SwissADME for designing other drug molecules.

Methods: SwissADME, an online tool for ADME prediction, was used along with Swiss Target Prediction to understand the targets of the drug. Further, experimental data was obtained from the available scientific literature.

Results: We found certain similarities between the predicted and experimental data. However, there were some variations, depending on the testing conditions. The results are interpreted ahead in the article.

Conclusion: Ethambutol’s predicted ADME properties are discussed and as per findings from results, it can be concluded that other drug molecules can be similarly predicted using these tools. Also, based on predicted data, we can reformulate and prepare some different preparations of the drug.

Keywords: Drug designing, ethambutol, swissADME, target prediction, bioavailability, ADME.

Graphical Abstract

[1]
PubChem. Ethambutol. Available from:. https://pubchem.ncbi.nlm. nih.gov/compound/14052 (Accessed 2021 May 17)
[2]
Fvasconcellos. Skeletal formula of ethambutol. Created using ACD/ChemSketch 10.0, Inkscape, and vim. 2009. Available from:. https://commons.wikimedia.org/wiki/File:Ethambutol.svg (Accessed 2021 Oct 23)
[3]
Chakraborty S, Rhee KY. Tuberculosis drug development: History and evolution of the mechanism-based paradigm. Cold Spring Harb Perspect Med 2015; 5(8): a021147.
[http://dx.doi.org/10.1101/cshperspect.a021147] [PMID: 25877396]
[4]
Drugs@FDA: FDA-Approved Drugs. Available from:. https://www. accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reports Search.process&rptName=2&reportSelectMonth=11&reportSelectYe ar=1967&nav (Accessed 2021 May 17)
[5]
Sciaky R, Ibemalle G, Berardi M, Larini G, Leone A. Novo processo para a producao de etambutol [Internet]. BR6915454D0, 1973. Available from:. https://patents.google.com/patent/BR6915454D0/en (Accessed 2021 May 17)
[6]
SwissADME. Swiss Institute of Bioinformatics. Available from:. http://www.swissadme.ch/
[7]
Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep 2017; 7(1): 42717.
[http://dx.doi.org/10.1038/srep42717] [PMID: 28256516]
[8]
Daina A, Zoete V. A BOILED-egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem 2016; 11(11): 1117-21.
[http://dx.doi.org/10.1002/cmdc.201600182] [PMID: 27218427]
[9]
Becker C, Dressman JB, Amidon GL, et al. Biowaiver monographs for immediate release solid oral dosage forms: ethambutol dihydrochloride. J Pharm Sci 2008; 97(4): 1350-60.
[http://dx.doi.org/10.1002/jps.21061] [PMID: 17879380]
[10]
Peets EA, Sweeney WM, Place VA, Buyske DA. The absorption, excretion, and metabolic fate of ethambutol in man. Am Rev Respir Dis 1965; 91(1): 51-8.
[http://dx.doi.org/10.1164/arrd.1965.91.1.51] [PMID: 14260000]
[11]
Holdiness MR. Clinical pharmacokinetics of the antituberculosis drugs. Clin Pharmacokinet 1984; 9(6): 511-44.
[http://dx.doi.org/10.2165/00003088-198409060-00003] [PMID: 6391781]
[12]
Fernandes J, Gattass CR. Topological polar surface area defines substrate transport by multidrug resistance associated protein 1 (MRP1/ABCC1). J Med Chem 2009; 52(4): 1214-8.
[http://dx.doi.org/10.1021/jm801389m] [PMID: 19193010]
[13]
Ursu O, Rayan A, Goldblum A, Oprea TI. Understanding drug‐likeness. WIREs Comput Mol Sci 2011; 1(5): 760-81.
[http://dx.doi.org/10.1002/wcms.52]
[14]
SwissTargetPrediction. Swiss Institute of Bioinformatics. Available from. http://www.swisstargetprediction.ch/
[15]
Daina A, Michielin O, Zoete V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res 2019; 47(W1): W357-64.
[http://dx.doi.org/10.1093/nar/gkz382] [PMID: 31106366]
[16]
Zoete V, Daina A, Bovigny C, Michielin O. SwissSimilarity: A web tool for low to ultra high throughput ligand-based virtual screening. J Chem Inf Model 2016; 56(8): 1399-404.
[http://dx.doi.org/10.1021/acs.jcim.6b00174] [PMID: 27391578]

Rights & Permissions Print Cite
Article Metrics
31
1
© 2024 Bentham Science Publishers | Privacy Policy